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Race and Ethnicity, Obesity, Metabolic Health, and Risk of
Cardiovascular Disease in Postmenopausal Women
Michelle D. Schmiegelow, MD; Haley Hedlin, PhD; Rachel H. Mackey, PhD, MPH; Lisa W. Martin, MD; Mara Z. Vitolins, DrPH;
Marcia L. Stefanick, PhD; Marco V. Perez, MD; Matthew Allison, MD, MPH; Mark A. Hlatky, MD

Background-—It is unclear whether obesity unaccompanied by metabolic abnormalities is associated with increased cardiovascular
disease risk across racial and ethnic subgroups.
Methods and Results-—We identiﬁed 14 364 postmenopausal women from the Women’s Health Initiative who had data on fasting
serum lipids and serum glucose and no history of cardiovascular disease or diabetes at baseline. We categorized women by body
mass index (in kg/m2) as normal weight (body mass index 18.5 to <25), overweight (body mass index 25 to <30), or obese (body
mass index ≥30) and by metabolic health, deﬁned ﬁrst as the metabolic syndrome (metabolically unhealthy: ≥3 metabolic
abnormalities) and second as the number of metabolic abnormalities. We used Cox proportional hazards regression to assess
associations between baseline characteristics and cardiovascular risk. Over 13 years of follow-up, 1101 women had a ﬁrst
cardiovascular disease event (coronary heart disease or ischemic stroke). Among black women without metabolic syndrome,
overweight women had higher adjusted cardiovascular risk than normal weight women (hazard ratio [HR] 1.49), whereas among white
women without metabolic syndrome, overweight women had similar risk to normal weight women (HR 0.92, interaction P=0.05).
Obese black women without metabolic syndrome had higher adjusted risk (HR 1.95) than obese white women (HR 1.07; interaction
P=0.02). Among women with only 2 metabolic abnormalities, cardiovascular risk was increased in black women who were overweight
(HR 1.77) or obese (HR 2.17) but not in white women who were overweight (HR 0.98) or obese (HR 1.06). Overweight and obese
women with ≤1 metabolic abnormality did not have increased cardiovascular risk, regardless of race or ethnicity.
Conclusions-—Metabolic abnormalities appeared to convey more cardiovascular risk among black women. ( J Am Heart Assoc.
2015;4:e001695 doi: 10.1161/JAHA.114.001695)
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O

besity has become a worldwide epidemic,1 so methods
to identify those at risk of obesity-related cardiovascular disease (CVD) morbidity and mortality are warranted.
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The excess cardiovascular risk of obese persons may be
attributable primarily to metabolic mediators rather than to
obesity per se,2,3 and insulin resistance has been suggested
as a key pathophysiological link between obesity and
cardiovascular risk.4 Some persons appear to be “metabolically healthy obese,”5,6 in that they are not insulin resistant
and lack most of the metabolic abnormalities composing the
metabolic syndrome.7 In white populations, the cardiovascular risk of the metabolically healthy obese group appears
to be no higher than that of metabolically healthy persons of
normal weight.5,8,9 In other racial and ethnic groups,
however, the cardiovascular risk among metabolically
healthy obese persons is largely unexplored, and may differ
from that among white persons; not only does the prevalence of cardiovascular risk factors differ across race and
ethnicity, but some risk factors, such as hypertension,
appear to be associated with a higher cardiovascular risk in
black persons.10,11
We aimed to characterize cardiovascular risk according to
obesity level and metabolic health status across racial and
ethnic subgroups. In identiﬁcation of persons with elevated
cardiovascular risk in relation to obesity, we also sought to
Journal of the American Heart Association
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m2] <18.5). Race or ethnicity was categorized as non-Hispanic
white women (hereafter referred to as white women), nonHispanic black women (hereafter referred to as black women),
and Hispanic women.

Exposure Deﬁnitions

Methods
Study Population
The Women’s Health Initiative (WHI) recruited a large
multiethnic cohort of postmenopausal women aged 50 to
79 years at baseline throughout the United States during
1993–1998. The WHI consisted of an observational study
cohort and 3 clinical trial cohorts (a diet modiﬁcation trial, a
menopausal hormone therapy trial, and/or a calcium/vitamin
D trial) that deﬁned and measured clinical variables uniformly
across all studies. The scientiﬁc rationale, study design,
eligibility criteria, and baseline characteristics of these studies
have been reported.12–15 The WHI studies were approved by
institutional review committees at each participating center,
and all participants gave written informed consent. The
present study included women from 2 biomarker subcohorts
of the WHI and its Extension Study (2005–2010): the SNP
Health Association Resource cohort (n=11 967), which comprised black and Hispanic participants from either the
observational trial or the clinical trial cohorts, and the
European American Hormone Trial subcohort (n=10 161),
which primarily comprised white women from the menopausal
hormone therapy trials.
The WHI excluded women with predicted survival of
<3 years and women with alcohol or drug dependency or
mental illness; the clinical trials also excluded women with
any invasive cancer in the previous 10 years, hepatitis or
cirrhosis, or blood pressure ≥200/105 mm Hg; and the
menopausal hormone therapy trials also excluded women
with a history of pulmonary embolus, deep venous thromboembolism, or hypertriglyceridemia. For the present study, we
excluded women with prior CVD, deﬁned as a previous history
of myocardial infarction, stroke, cardiac catheterization,
percutaneous coronary intervention, coronary artery bypass
surgery, heart failure, atrial ﬁbrillation, or aortic aneurysm at
entry, or with prior diabetes, deﬁned as a self-reported
medical history of diabetes, treatment with glucose-lowering
agents, or a fasting serum glucose level ≥126 mg/dL
(≥7.0 mmol/L). Because of insufﬁcient data for analysis, we
also excluded women with missing data on pertinent variables
(height, weight, waist circumference, age, smoking, systolic or
diastolic blood pressure, treatment for hypertension, triglycerides, high-density lipoprotein cholesterol [HDL-C], fasting
serum glucose, baseline hormone use, or any of the exclusion
variables), women who provided data only at baseline, and
women who were underweight (body mass index [BMI; in kg/
DOI: 10.1161/JAHA.114.001695

During the baseline clinic visit, each study participant
completed self-administered questionnaires on medical history, smoking, diet, physical activity, and other lifestylerelated factors and had blood pressure, weight, and height
measured. Waist circumference was measured to nearest
0.5 cm at the narrowest part of the torso at the end of a
normal expiration. Women in the biomarker studies had
blood samples drawn after a 12-hour fast. Glucose was
analyzed using the Gluco-quant glucose/hexokinase reagent
(Roche), triglycerides were analyzed using the Triglyceride
GB reagent (Roche), and HDL-C was analyzed using the HDLC Plus third-generation direct method (Roche), all on a
Roche Modular P chemistry analyzer. All assays for the
biomarker studies were done on serum by the University of
Minnesota Medical Center laboratory, and average assay
correlation variances were 2% for glucose, 2% for triglycerides, and 3% for HDL-C.
We deﬁned the metabolic abnormalities composing the
metabolic syndrome according to the 2009 joint interim
statement of the International Diabetes Federation and the
American Heart Association/National Heart, Lung, and Blood
Institute,7 based on increased waist circumference ≥80 cm,
increased level of triglycerides ≥150 mg/dL (≥1.7 mmol/L),
decreased level of HDL-C <50 mg/dL (<1.3 mmol/L),
increased blood pressure with either systolic blood pressure
≥130 mm Hg or diastolic blood pressure ≥85 mm Hg or
treatment with antihypertensive drugs, and impaired fasting
serum glucose ≥100 mg/dL (5.6 mmol/L). Consistent with
other studies, we deﬁned metabolically unhealthy as the
presence of ≥3 metabolic abnormalities (metabolic syndrome)
and metabolically healthy as ≤2 metabolic abnormalities.16

Primary End Point
The primary outcome was time to ﬁrst CVD event deﬁned as
nonfatal and fatal coronary heart disease or ischemic stroke,
identiﬁed using annual mailed questionnaires (semiannual for
clinical trials, response rates >95%) and adjudicated locally
and centrally by physicians blinded to exposure data by use of
medical records and standard criteria.17 Standardized criteria
for electrocardiographic changes, elevated cardiac enzymes,
or both were used to deﬁne nonfatal myocardial infarction. A
diagnosis of ischemic stroke required a hospital admission
with rapid onset of neurological deﬁcit persisting >24 hours,
attributed to occlusion of cerebral or extracranial arteries with
Journal of the American Heart Association
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investigate whether the standard deﬁnition of metabolically
healthy obese applied to the various racial and ethnic
subgroups by quantifying the number and the type of
metabolic syndrome components.
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Statistical Methods
We categorized the study population by metabolic health
status within each BMI category: normal weight (18.5 to
<25.0), overweight (25.0 to <30.0), or obese (BMI ≥30.0).
We assessed the associations between obesity and
metabolic subtypes and the risk of CVD by use of multivariable Cox proportional hazards regression. Because the aim of
the study was to examine the race-speciﬁc cardiovascular risk
according to obesity and metabolic health subtypes, analyses
were performed separately by race or ethnicity (white, black,
Hispanic). Normal weight women with <3 (0, 1, or 2)
metabolic abnormalities were used as a reference category
in all analyses unless otherwise stated. Metabolic abnormalities were categorized using 3 different approaches. First,
metabolic abnormalities were categorized according to the
binary metabolic syndrome (≥3 metabolic abnormalities, yes
or no) to allow for direct comparisons between prior studies
and our ﬁndings for white women and, afterward, to compare
our results across races and ethnicities. Second, metabolic
abnormalities were categorized as accumulated numbers of
metabolic abnormalities to further explore our ﬁndings. Given
that almost all overweight (79%) and obese (98%) women had
a waist circumference ≥80 cm, groups with 0 or 1 metabolic
abnormality were combined for overweight and obese women
(leaving 4 categories: 0 to 1, 2, 3, or ≥4 metabolic
abnormalities). To enable comparison with primary analyses,
the reference category comprised normal weight women with
≤2 metabolic abnormalities (without the metabolic syndrome).
Third, we assessed the associations between the most
frequent combinations of the metabolic syndrome components and cardiovascular risk (no metabolic abnormalities as
the reference category) to explore whether speciﬁc combinations of abnormalities drove our results. Due to few events in
Hispanic women, we conducted analyses according to
combinations of metabolic abnormalities only in white and
black women. The ﬁrst 2 approaches were categorized based
on metabolic abnormalities and BMI category. The categories
in the third approach were independent of BMI category but
adjusted for BMI and waist circumference. All categories were
nominal; no ordering was assumed.
In each approach, we adjusted for age, smoking, and
hormone use at baseline in primary analyses. All models
were stratiﬁed by hormone therapy trial study arm and
hysterectomy status because stratiﬁcation allowed us to
DOI: 10.1161/JAHA.114.001695

control for potential confounding. In separate models, we
also adjusted for physical activity, education, parity (number
of term pregnancies), and low-density lipoprotein cholesterol
(LDL-C) and treatment with lipid-lowering drugs. Overall
incidence rates per 1000 person-years for each race or
ethnicity were age standardized to 1998 US population data
using the Surveillance, Epidemiology, and End Results (SEER)
program. The proportional hazards assumption was assessed
by visual examination of Schoenfeld residual plots, which
appeared to be satisﬁed unless otherwise indicated. To
explore whether associations between obesity and metabolic
health subtypes and cardiovascular risk differed according to
race or ethnicity, we tested for effect modiﬁcation through
the use of statistical interaction terms in the metabolic
syndrome model, but not in the models with metabolic
health deﬁned by number of metabolic abnormalities or
combination of metabolic syndrome components due to lack
of statistical power. Furthermore, we included only white and
black women because of the small number of Hispanic
women; we tested whether the associations between
metabolic health status and cardiovascular risk within each
BMI category differed between white and black women by
use of pair-wise comparison tests.
In sensitivity analyses we included women with diabetes at
baseline. In additional sensitivity analyses, we used the higher
threshold for impaired fasting glucose of 110 mg/dL (6.1
mmol/L) used by European guidelines18 and the World Health
Organization because several studies have found no incremental risk with a threshold of 100 mg/dL.19,20 We also
conducted a sensitivity analysis in which all women receiving
hormone therapy at baseline or in the active intervention arm
of the hormone therapy trials were excluded. Moreover, we
evaluated a different deﬁnition of metabolically unhealthy

Figure 1. Flowchart of study. *Cardiac arrest, heart failure,
cardiac catheterization, atrial ﬁbrillation, aortic aneurism,
angioplasty of coronary arteries, coronary bypass surgery, or
other heart problems. BMI indicates body mass index; EA HT,
European American Hormone Trial subcohort; SHARe, SNP
Health Association Resource cohort.
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infarction and without evidence of other cause. Fatal events
were conﬁrmed by documentation in hospital, by autopsy
reports, or both. The participants were followed until December 31, 2010, or until ﬁrst CVD event, loss to follow-up, death
from any cause, or last visit prior to the end of Extension
Study I at December 31, 2010, whichever came ﬁrst.
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Table 1. Baseline Characteristics of the Analytic Cohort of Postmenopausal Women According to BMI Categories (n=14 364)
Normal Weight (BMI 18.5 to <25)

Overweight (BMI 25 to <30)

Obese (BMI ≥30)

n=3625

n=5335

n=5404

50 to 59

28

31

37

60 to 69

42

45

45

70 to 79

30

24

18

Non-Hispanic white

56

46

42

Black or African American

25

35

43

Hispanic/Latino

19

19

15

≥80 cm

23

79

98

≥88 cm

4

36

88

High glucose (≥100 mg/dL)

14

22

34

Glucose (mg/dL), mean (SD)

90.3 (9.4)

92.9 (9.9)

96.3 (10.9)

High measured blood pressure* (SBP ≥130 and/or DBP ≥85)

41

49

56

Never hypertensive

77

66

55

Untreated hypertensive

6

9

9

Treated hypertensive

17

25

35

High triglycerides (≥150 mg/dL)

18

31

34

Low HDL-C (≤50 mg/dL)

23

38

48

25

42

49

LDL-C (mg/dL), median (IQR)

142 (120 to 168)

149 (125 to 174)

148 (125 to 174)

Lipid-lowering drugs‡

10

14

12

Never

52

53

53

Former

35

38

40

Current

13

9

7

<1

24

30

43

1 to 2

15

17

17

2 to 3.5

19

20

17

≥3.5

41

33

23

Never

58

58

62

Past

21

20

19

Current

21

21

19

19

20

20

Age, y

Race/ethnicity

Waist circumference

Hypertension*

Insulin resistance

†

‡

Smoking

Total minutes of physical activity, hours/week

Hormone use

HRT arm and hysterectomy status
Not randomized to HRT plus no hysterectomy
Not randomized to HRT plus hysterectomy

17

21

23

E-alone intervention

10

11

13

E-alone control

9

12

13
Continued

DOI: 10.1161/JAHA.114.001695
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Table 1. Continued
Normal Weight (BMI 18.5 to <25)

Overweight (BMI 25 to <30)

Obese (BMI ≥30)

n=3625

n=5335

n=5404

E+P intervention

22

18

16

E+P control

22

18

15

Northeast

22

20

20

South

31

34

36

Midwest

21

21

24

West

26

25

21

Did not go to school

0

0

0

Grade school (1 to 4 years)

1

1

1

Grade school (5 to 8 years)

1

2

2

Some high school (9 to 11 years)

4

5

6

High school diploma or GED

17

17

19

Vocational or training school

11

12

13

Some college or associate degree

26

27

28

College degree or bachelor degree

10

9

8

Some postgraduate or professional

10

9

8

Master degree

16

14

12

Doctoral degree

2

2

2

Never pregnant

9

7

7

Never had term pregnancy

4

3

4

1

11

10

10

2

23

22

21

3

22

23

21

4

16

16

16

≥5

14

18

21

US region

Education

‡

Number of term pregnancies‡

Data are shown as percentages, except as noted. BMI indicates body mass index; DBP, diastolic blood pressure; E+P, estrogen plus progestin; E-alone, estrogen alone; GED, General
Educational Development; HDL-C, high-density lipoprotein cholesterol; HRT, hormone replacement therapy; IQR, interquartile range; LDL-C, low-density lipoprotein cholesterol; SBP,
systolic blood pressure.
*In the models, high blood pressure comprised high measured blood pressure and treated hypertension.
†
Triglycerides/HDL-C >2.47 (75th percentile among healthy-weight women).
‡
Variables with missing data: LDL-C (n=118), lipid-lowering drugs (n=5), education (n=122), and number of term pregnancies (n=92).

obese, that is, by being obese, deﬁned as a BMI ≥30 or waist
circumference ≥80 cm, in addition to at least 2 other
metabolic syndrome components.9 In the latter analyses,
normal weight and overweight women with a waist circumference <80 cm but ≥2 metabolic abnormalities were
considered metabolically unhealthy, albeit not obese, and
categorized separately. Finally, we explored the associations
between presence of the metabolic syndrome and CVD risk
according to BMI as a continuous variable using normal
weight, metabolically healthy women as reference.
DOI: 10.1161/JAHA.114.001695

Analyses were performed with SAS software, version 9.3
(SAS Institute, Inc), and R 3.0 (R Foundation for Statistical
Computing).

Results
Of 22 128 women with biomarker data, 7438 met exclusion
criteria and 326 had missing data on covariates, yielding a ﬁnal
analytic cohort of 14 364 women (Figure 1). The median age of
the study population was 64 years (interquartile range 57 to 69
Journal of the American Heart Association
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White

Black

Hispanic

n=6741

n=5102

n=2521

50 to 59

15

45

53

60 to 69

48

42

39

70 to 79

37

13

9

Normal weight (18.5 to <25)

30

18

27

Overweight (25 to <30)

37

36

41

Obese (≥30)

33

46

32

≥80 cm

71

77

66

≥88 cm

48

52

38

Age, y

BMI category

Waist circumference

High glucose (≥100 mg/dL)

27

23

22

Glucose (mg/dL), mean (SD)

95 (10)

93 (11)

92 (10)

High blood pressure (SBP ≥130 and/or DBP ≥85)

50

55

38

Never hypertensive

70

52

76

Untreated hypertensive

8

9

8

Treated hypertensive

22

38

16

Hypertension

High triglycerides (≥150 mg/dL)

35

15

40

Low HDL-C (≤50 mg/dL)

42

31

43

Insulin resistance*

47

26

52

LDL-C (mg/dL), median (IQR)

152 (130 to 176)

143 (119 to 171)

141 (119 to 165)

Lipid-lowering drugs†

12

12

12

†

Smoking
Never

51

49

63

Former

40

39

30

Current

9

12

6

Total minutes of physical activity, hours/week
<1

30

37

35

1 to 2

17

16

16

2 to 3.5

19

18

18

≥3.5

34

28

31

Never

66

57

47

Past

26

15

14

Current

8

28

38

0

36

41

Hormone use

HRT arm and hysterectomy status
Not randomized to HRT plus no hysterectomy
Not randomized to HRT plus hysterectomy

0

42

32

E-alone intervention

18

6

5

E-alone control

18

7

6
Continued
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Table 2. Baseline Characteristics of the Analytic Cohort of Postmenopausal Women According to Race or Ethnicity (n=14 364)
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Table 2. Continued
White

Black

Hispanic

n=6741

n=5102

n=2521

E+P intervention

33

5

9

E+P control

31

5

8

Northeast

25

17

12

South

20

49

42

Midwest

28

23

4

West

27

11

42

Did not go to school

0

0

0

Grade school (1 to 4 years)

0

0

4

Grade school (5 to 8 years)

1

1

7

Some high school (9 to 11 years)

4

6

8

High school diploma or GED

22

13

17

Vocational or training school

12

12

12

US region

Education

†

Some college or associate degree

29

26

25

College degree or bachelor degree

9

9

7

Some postgraduate or professional

0

9

6

Master degree

11

19

9

Doctoral degree

2

2

2

7

7

9

Number of term pregnancies†
Never pregnant
Never had term pregnancy

2

6

3

1

7

16

9

2

20

25

22

3

25

18

21

4

18

12

16

≥5

20

15

19

Data are shown as percentages, except as noted. BMI indicates body mass index; DBP, diastolic blood pressure; E+P, estrogen plus progestin; E-alone, estrogen alone; HDL-C, high-density
lipoprotein cholesterol; HRT, hormone replacement therapy; IQR, interquartile range; LDL-C, low-density lipoprotein cholesterol; SBP, systolic blood pressure.
*Triglycerides/HDL-C >2.47 (75th percentile among healthy-weight women.
†
Variables with missing data: LDL-C (n=118), lipid-lowering drugs (n=5), education (n=122), and number of term pregnancies (n=92).

years), and 47% were white, 36% were black, and 18% were
Hispanic. As BMI increased, all components of the metabolic
syndrome became more common, as did clustering of metabolic abnormalities (Table 1). Elevated blood pressure was
more common in black women, but untreated hypertension
was uncommon in all race and ethnicity categories (Table 2).
High triglycerides and low HDL-C were more common in white
and Hispanic women than in black women (Table 2). Over a
median follow-up of 13 years (interquartile range 12 to
14 years), 1101 women (7.7%) had a ﬁrst cardiovascular event
(718 coronary heart disease, 411 ischemic stroke, 48 both
events), for an incidence rate of 6.4 per 1000 person-years.
DOI: 10.1161/JAHA.114.001695

Race- or ethnicity-speciﬁc incidence rates of CVD were 8.8 per
1000 person-years (95% conﬁdence interval [CI] 8.1 to 9.6 per
1000 person-years) for white women, 4.8 per 1000 personyears (CI 4.2 to 5.5 per 1000 person-years) for black women,
and 3.2 per 1000 person-years (CI 2.5 to 4.2 per 1000 personyears) for Hispanic women.

Metabolically Healthy Deﬁned by the Metabolic
Syndrome
Women who were metabolically unhealthy (based on the
standard binary deﬁnition of metabolic syndrome) had
Journal of the American Heart Association
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HR (CI)

White women

Metabolically healthy
Normal weight
Overweight
Obese
Metabolically unhealthy
Normal weight
Overweight
Obese
B

Events, no./total

(ref)
0.92 (0.72−1.17)
1.07 (0.80−1.42)

167/1707
114/1364
66/737

2.13 (1.60−2.85)
1.41 (1.13−1.76)
1.51 (1.22−1.86)

64/313
151/1106
193/1514

(ref)
1.49 (0.93−2.39)
1.95 (1.23−3.08)

26/831
54/1259
63/1239

Black women

Metabolically healthy
Normal weight
Overweight
Obese
Metabolically unhealthy
Normal weight
Overweight
Obese
C

ORIGINAL RESEARCH
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5.61 (2.91−10.78) 14/92
2.03 (1.23−3.34) 38/581
2.49 (1.59−3.92) 72/1100

Hispanic women

Metabolically healthy
Normal weight
Overweight
Obese
Metabolically unhealthy
Normal weight
Overweight
Obese
0.5

1.0

(ref)
1.05 (0.52−2.14)
1.00 (0.41−2.45)

16/591
15/598
7/310

3.08 (1.29−7.37)
1.33 (0.65−2.71)
1.67 (0.84−3.35)

8/91
15/427
18/504

2.0 3.0 5.0 10.0 15.0

Figure 2. Hazard ratios of the composite outcome of coronary heart disease and ischemic stroke by BMI
categories and the presence of the metabolic syndrome in (A) white women, (B) black women, and (C)
Hispanic women. Healthy-weight women with <3 (0, 1, or 2) metabolic abnormalities were used as the
reference in all models; models were adjusted for age, smoking, and hormone use at baseline and stratiﬁed
by hormone therapy trial study arm and hysterectomy status. BMI indicates body mass index; HR, hazard
ratio; ref, reference.

increased CVD risk regardless of BMI category in all racial and
ethnic groups (Figure 2), although there were too few events
among the Hispanic women for precise estimates. White
women who were overweight or obese but metabolically
healthy had a cardiovascular risk that was not statistically
different from normal weight metabolically healthy women
(Figure 2A). Metabolically healthy obese black women,
however, had a signiﬁcantly increased cardiovascular risk,
and overweight metabolically healthy black women showed
a trend toward increased cardiovascular risk compared with
normal weight metabolically healthy women (Figure 2B). The
associations between metabolic health status and cardiovascular risk differed signiﬁcantly between white and black
women; statistically signiﬁcant interactions were found
between BMI categories and race or ethnicity (white or
black) within metabolic health categories (Figure 2). Among
the metabolically healthy women, overweight black women
had higher cardiovascular risk than overweight white women
(interaction P=0.05), and obese black women had higher

DOI: 10.1161/JAHA.114.001695

cardiovascular risk than obese white women (interaction
P=0.02). Among the metabolically unhealthy women, normal
weight black women had higher cardiovascular risk than
normal weight white women (interaction P=0.01), overweight
black women had a trend toward higher cardiovascular risk
than overweight white women (interaction P=0.18), and
obese black women had higher cardiovascular risk than
obese white women (interaction P=0.04).

Metabolically Healthy Deﬁned by Number of
Metabolic Disorders
We found a graded association between increasing number of
metabolic abnormalities and increased cardiovascular risk in
each BMI category in both white and black women (Figure 3A
and 3B). Furthermore, black women with just 2 metabolic
abnormalities who were overweight or obese had increased
risk of CVD (Figure 3B), even though they would be considered metabolically healthy based on the standard binary
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White women

Normal weight
#abnl
Overweight
#abnl

Obese
#abnl

B

Events, no./total

0–2
3
≥4

(ref)
1.84 (1.29−2.62)
2.81 (1.85−4.26)

167/1707
38/210
26/103

0–1
2
3
≥4

0.83 (0.59−1.16)
0.98 (0.74−1.30)
1.15 (0.86−1.53)
1.71 (1.32−2.22)

43/605
71/759
65/595
86/511

0–1
2
3
≥4

1.07 (0.67−1.71)
1.06 (0.76−1.47)
1.02 (0.75−1.40)
1.84 (1.47−2.32)

20/216
46/521
54/635
139/879

0–2
3
≥4

(ref)
4.57 (2.13−9.80)
9.65 (3.67−25.36)

26/831
9/68
5/24

0–1
2
3
≥4

1.10 (0.59−2.05)
1.77 (1.07−2.92)
1.97 (1.13−3.44)
2.14 (1.11−4.12)

16/554
38/705
24/374
14/207

0–1
2
3
≥4

1.30 (0.64−2.65)
2.17 (1.35−3.48)
2.33 (1.43−3.81)
2.81 (1.65−4.81)

11/330
52/909
43/699
29/401

0–2
3
≥4

(ref)
3.41 (1.31−8.88)
2.34 (0.52−10.50)

16/591
6/63
2/28

0–1
2
3
≥4

0.54 (0.18−1.62)
1.61 (0.74−3.50)
0.91 (0.35−2.34)
1.92 (0.84−4.37)

4/304
11/294
6/249
9/178

0–1
2
3
≥4
0.5

1.74 (0.58−5.26)
0.64 (0.18−2.20)
2.06 (0.96−4.42)
1.22 (0.47−3.18)

4/110
3/200
12/287
6/217

Black women

Normal weight
#abnl
Overweight
#abnl

Obese
#abnl

C
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HR (CI)
A

Hispanic women

Normal weight
#abnl
Overweight
#abnl

Obese
#abnl

1.0

2.0 3.0 5.0 10.0 15.0

Figure 3. Hazard ratios of the composite outcome of coronary heart disease and ischemic stroke by
BMI categories in (A) white women, (B) black women, and (C) Hispanic women, according to
incremental number of metabolic abnormalities. Normal weight women with <3 (0, 1, or 2) metabolic
abnormalities were used as the reference in all models; models were adjusted for age, smoking, and
hormone use at baseline and stratiﬁed by hormone therapy trial study arm and hysterectomy status.
#abnl indicates number of metabolic abnormalities; BMI, body mass index; HR, hazard ratio; ref,
reference.

deﬁnition of metabolic syndrome (Figure 1), especially
because 1 of these abnormalities was abdominal obesity for
79% of overweight women and 98% of obese women. In
contrast, white obese women with 3 metabolic abnormalities
did not have a statistically signiﬁcantly increased cardiovasDOI: 10.1161/JAHA.114.001695

cular risk (Figure 3A), although the standard binary deﬁnition
of metabolic syndrome would categorize them as metabolically unhealthy. The number of Hispanic women in each
category was too small to permit precise risk estimates
(Figure 3C).
Journal of the American Heart Association
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HR (CI)

White women
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A
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Events, no./total

Combination of abnormalities

B

None
Elevated BP only

(ref)
1.29 (0.99–1.69)

98/1,338
128/1275

Low HDL-C only
High glucose only

1.29 (0.87–1.91)
0.71 (0.41–1.25)

34/375
14/257

High TG only

1.24 (0.75–2.06)

18/202

Low HDL-C and elevated BP

2.65 (1.95–3.60)

75/407

High glucose and elevated BP

1.45 (1.01–2.10)

42/398

Any other 2

1.13 (0.83–1.54)

73/871

Low HDL-C, elevated BP, high TG

2.19 (1.64–2.93)

96/616

High glucose, low HDL-C, elevated BP

2.37 (1.60–3.51)

36/212

Any other 3

2.07 (1.45–2.94)

50/336

All 4

2.83 (2.08–3.84)

91/454

None
Elevated BP only

(ref)
1.59 (1.02–2.46)

27/991
89/1646

Low HDL-C only
High glucose only

2.03 (1.09–3.79)
0.70 (0.24–2.01)

16/300
4/172

Black women

Combination of abnormalities

High TG only

1.91 (0.58–6.32)

3/51

Low HDL-C and elevated BP

1.88 (1.12–3.15)

34/509

High glucose and elevated BP

1.03 (0.55–1.90)

17/435

Any other 2

2.16 (1.24–3.76)

24/319

Low HDL-C, elevated BP, high TG

2.06 (1.09–3.92)

15/205

High glucose, low HDL-C, elevated BP

1.96 (1.03–3.74)

15/219

Any other 3

3.08 (1.56–6.09)

13/107

All 4

1.78 (0.85–3.75)

10/148

0.25 0.50 1.00 2.00 5.00 10.00

Figure 4. Hazard ratios of the composite outcome of coronary heart disease and ischemic stroke
according to BMI categories and speciﬁc combinations of metabolic abnormalities in (A) white women and
(B) black women. Women with no metabolic abnormalities were used as the reference in all models, and all
models were adjusted for age, smoking, BMI, waist circumference, and hormone use at baseline and
stratiﬁed by hormone therapy trial study arm and hysterectomy status. BMI indicates body mass index; BP,
blood pressure; HDL-C, high density lipoprotein-cholesterol; HR, hazard ratio; ref, reference; TG,
triglycerides.

Cardiovascular Risk According to Combination of
Metabolic Abnormalities
We assessed whether speciﬁc combinations of risk factors
conveyed greater degrees of cardiovascular risk by combining
all white women (Figure 4A) and black women (Figure 4B)
and applying a model that adjusted for BMI and waist
circumference. There was no strong evidence that any
particular combination of 2 (or 3) factors conveyed
substantially different risk than any other combination
DOI: 10.1161/JAHA.114.001695

(Figure 4). Furthermore, although the sample sizes were
small in the racial and ethnic subgroups, elevated blood
pressure did not appear to be associated with a different
CVD risk for black women compared with for white women
(interaction P=0.90).

Sensitivity Analyses
The main ﬁndings of this study were not changed when
women with diabetes at baseline were included and catego-
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Metabolic Abnormalities

White

Black

Hispanic

n=7508

n=6043

n=2802

HR

CI

HR

CI

HR

CI

0 to 2

Ref

—

Ref

—

Ref

—

3

1.96

1.41 to 2.73

3.60

1.76 to 7.36

2.62

1.02 to 6.68

≥4

2.57

1.76 to 3.75

6.51

2.98 to 14.21

3.30

1.09 to 9.98

0 to 1

0.79

0.57 to 1.11

0.99

0.55 to 1.79

0.48

0.16 to 1.42

2

0.99

0.76 to 1.30

1.59

0.99 to 2.54

1.34

0.63 to 2.85

3

1.15

0.87 to 1.51

1.81

1.10 to 2.98

0.83

0.35 to 2.01

≥4

1.89

1.49 to 2.37

3.29

2.03 to 5.31

2.30

1.15 to 4.58

0 to 1

1.02

0.64 to 1.63

1.18

0.60 to 2.32

1.51

0.51 to 4.49

2

1.05

0.77 to 1.44

1.84

1.18 to 2.88

0.68

0.23 to 2.04

3

1.12

0.85 to 1.49

2.69

1.77 to 4.08

2.07

1.04 to 4.11

≥4

1.96

1.60 to 2.40

3.21

2.09 to 4.91

1.53

0.74 to 3.20

Normal weight

Overweight

Obese

All models were adjusted for age, smoking, and hormone use at baseline and stratiﬁed by hormone therapy trial study arm and hysterectomy status. HR indicates hazard ratio.
*Women with diabetes were categorized as having an abnormal glucose metabolism regardless of fasting glucose levels.

rized as fulﬁlling the criterion for impaired fasting glucose (ie,
glucose ≥100 mg/dL) (Table 3) or when we used the higher
threshold for impaired fasting glucose of 110 mg/dL in the

primary study cohort (Table 4). Following exclusion of all
women receiving hormone therapy at baseline, the population
for these sensitivity analyses comprised 3057 white women,

Table 4. HRs of Cardiovascular Disease According to Body Mass Index and Metabolic Health Deﬁning Impaired Glucose
Metabolism as Fasting Glucose ≥110 mg/dL in a Cohort of Postmenopausal Women

Metabolic Abnormalities

White

Black

Hispanic

n=6741

n=5102

n=2521

HR

CI

HR

CI

HR

CI

Normal weight
0 to 2

Ref

—

Ref

—

Ref

—

3

1.75

1.18 to 2.59

2.81

1.09 to 7.29

3.11

1.14 to 8.54

≥4

3.02

1.97 to 4.64

11.02

4.23 to 28.69

1.47

0.19 to 11.22

0 to 1

0.72

0.52 to 1.00

0.96

0.53 to 1.72

0.76

0.32 to 1.84

2

1.07

0.82 to 1.38

1.61

1.00 to 2.59

1.18

0.53 to 1.81

3

1.17

0.88 to 1.55

2.11

1.25 to 3.58

0.96

0.40 to 2.32

≥4

1.76

1.33 to 2.33

1.29

0.57 to 2.95

1.81

0.75 to 4.37

0 to 1

0.87

0.55 to 1.37

1.18

0.61 to 2.28

2.02

0.79 to 5.15

2

1.05

0.77 to 1.42

1.73

1.11 to 2.71

0.53

0.16 to 1.81

3

1.24

0.94 to 1.64

2.56

1.61 to 4.07

1.45

0.66 to 3.12

≥4

1.84

1.45 to 2.35

2.47

1.39 to 4.37

1.50

0.58 to 3.84

Overweight

Obese

All models were adjusted for age, smoking, and hormone use at baseline and stratiﬁed by hormone therapy trial study arm and hysterectomy status. HR indicates hazard ratio.
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Table 3. HRs of Cardiovascular Disease According to Body Mass Index and Metabolic Health Including Women With Diabetes*

Race/Ethnicity, BMI, Metabolism, and CVD Risk

Schmiegelow et al

Binary Model

White

Black

Hispanic

n=6741

n=5102

n=2521

HR

CI

HR

CI

HR

CI

Normal weight

Ref

—

Ref

—

Ref

—

Overweight

1.05

0.81 to 1.37

1.54

0.95 to 2.52

1.30

0.60 to 2.78

1.25

0.92 to 1.69

1.85

1.15 to 3.00

1.13

0.44 to 2.91

2.09

1.54 to 2.82

1.24

0.50 to 3.05

3.17

1.32 to 7.61

2.60

1.84 to 3.67

6.18

3.00 to 12.73

2.05

0.56 to 7.44

Metabolically healthy*

Obese
Metabolically unhealthy

†

Normal weight, WC <80 cm
Normal weight, WC ≥80 cm

‡

Overweight, WC <80 cm

1.18

0.65 to 2.14

0.88

0.26 to 2.95

1.69

0.47 to 6.03

Overweight, WC ≥80 cm‡

1.66

1.31 to 2.12

1.88

1.11 to 3.19

1.32

0.59 to 2.96

Obese‡

1.74

1.38 to 2.20

2.46

1.53 to 3.94

1.88

0.89 to 3.98

BMI indicates body mass index; HR, hazard ratio; WC, waist circumference.
*Metabolically healthy deﬁned as having <2 metabolic abnormalities.
†
Metabolically unhealthy deﬁned as having ≥2 metabolic abnormalities.
‡
Metabolically unhealthy obese: obese (WC ≥80 cm or BMI ≥30) and ≥2 additional metabolic abnormalities.

3217 black women, and 1243 Hispanic women. Although
limited by few events, particularly among nonwhite participants, the hazard ratios did not change considerably, leaving

our main ﬁndings unaltered. Furthermore, our results were
unchanged when we deﬁned metabolically unhealthy as being
obese (waist circumference ≥80 cm or BMI ≥30) in addition

Table 6. HRs of Cardiovascular Disease in a Cohort of Postmenopausal Women According to BMI and Metabolic Health Using a
Different Categorization*

Numeric Model

White

Black

Hispanic

n=6741

n=5102

n=2521

HR

CI

HR

CI

HR

CI

0 to 1

Ref

—

Ref

—

Ref

—

2

2.02

1.49 to 2.73

1.72

0.79 to 3.73

1.80

0.63 to 5.18

≥3

2.79

1.98 to 3.95

6.09

2.71 to 13.69

4.72

1.81 to 12.28

0

0.84

0.56 to 1.27

1.07

0.51 to 2.26

0.47

0.11 to 2.12

1

1.15

0.87 to 1.54

1.72

1.04 to 2.86

1.77

0.80 to 3.90

2

1.33

0.99 to 1.79

1.51

0.84 to 2.72

0.50

0.14 to 1.79

≥3

1.95

1.48 to 2.56

2.15

1.13 to 4.09

2.48

1.11 to 5.58

0

1.27

0.78 to 2.06

1.33

0.65 to 2.75

2.09

0.67 to 6.52

1

1.24

0.88 to 1.74

2.02

1.23 to 3.32

0.71

0.20 to 2.54

2

1.16

0.83 to 1.60

2.29

1.38 to 3.82

2.32

1.03 to 5.25

≥3

2.15

1.68 to 2.75

2.68

1.54 to 4.67

1.37

0.50 to 3.72

Normal weight

Overweight

Obese

BMI indicates body mass index; HR, hazard ratio.
*Waist circumference not included, and the reference category was deﬁned as <2 metabolic abnormalities to make the models comparable; metabolically healthy obese was deﬁned as
being obese (waist circumference ≥80 cm or BMI ≥30) and having <2 additional metabolic abnormalities.
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Table 5. HRs of Cardiovascular Disease in a Cohort of Postmenopausal Women According to BMI and Metabolic Health Using a
Different Categorization*

Race/Ethnicity, BMI, Metabolism, and CVD Risk

Schmiegelow et al

Hazard ratio
3
0

1

2

BMI>25 kg/m2 and <3 metabolic abnormalities
>3 metabolic abnormalities

Discussion
25

30

35

40
BMI (kg/m2)

BMI>25 kg/m2 and <3 metabolic abnormalities
>3 metabolic abnormalities

0

2

4

6

Hazard ratio
8
10

B Black women

25

30

35

C Hispanic women*

40
BMI (kg/m2)

BMI>25 kg/m2 and <3 metabolic abnormalities
>3 metabolic abnormalities

0

20

40

Hazard ratio
60
80

to having at least 2 metabolic abnormalities (Tables 5 and 6).
Analyses examining associations between the metabolic
syndrome and CVD risk, treating BMI as continuous,
conﬁrmed our ﬁndings that the metabolically healthy obese
concept applied to white women but not to all races and
ethnicities (Figure 5). Finally, self-reported physical activity,
education, parity, and LDL-C and lipid-lowering drugs did not
change any of the estimates considerably (data not shown).

25

30

35

40
BMI (kg/m2)

Figure 5. Hazard ratios of the composite outcome of coronary heart disease and ischemic
stroke according to presence of the metabolic
syndrome by increasing body mass index (BMI) in
(A) white women, (B) black women, and (C)
Hispanic women. Healthy-weight women with <3
(0, 1, or 2) metabolic abnormalities were used as
the reference in all models; models were adjusted
for age, smoking, and hormone use at baseline
and stratiﬁed by hormone therapy trial study arm
and hysterectomy status. The shaded regions
around the lines gives the 95% conﬁdence band,
the standard error, for the mean. *Please note
that the scale of the y-axis differs for white (0 to
3), black (0 to 10), and Hispanic (0 to 80) women,
so the widths of the CIs are not comparable.

DOI: 10.1161/JAHA.114.001695

In this prospective study of postmenopausal women without
diabetes or prior CVD, the risk of developing CVD was more
strongly associated with the presence of metabolic abnormalities than with the presence of obesity, regardless of racial or
ethnic background. Furthermore, metabolic abnormalities
appeared to confer more cardiovascular risk among black
women than among white women. Almost all prior studies of
obesity, metabolic health, and cardiovascular risk have been
limited to white participants and have relied on the presence or
absence of metabolic syndrome to deﬁne metabolic
health.5,9,16 Our ﬁnding that obesity in white women was not
associated with increased cardiovascular risk unless accompanied by the metabolic syndrome conﬁrms the results of
other studies.8,9 Our most novel ﬁnding was that black women
who were overweight or obese had elevated cardiovascular
risk even when they did not have the metabolic syndrome. It
appeared that the cardiovascular risk was elevated in black
women by the presence of only 2 or 3 metabolic abnormalities
to a degree that would require ≥4 metabolic abnormalities
among white women (Figure 2). The metabolic syndrome itself
has already been evaluated extensively and found to be no
greater than the sum of its parts.21,22 This study further
suggests that the use of the “metabolic syndrome” to deﬁne
the metabolically healthy obese group appears to underestimate risk among black women and to overestimate cardiovascular risk in white women. Instead, an individualized
approach in which the clinician considers the sum and the
type of metabolic syndrome components in light of the
patient’s overall risk proﬁle should be encouraged, especially
when applied to populations other than white.
It has been controversial whether metabolically healthy
obesity is a valid concept, and our study suggests that this
concept may not apply to black women. A recent metaanalysis and systematic review found that the lower cardiovascular risk in metabolically healthy obese persons was
documented only in studies that had limited follow-up
(<10 years of follow-up).16 The ﬁndings, however, were
unadjusted and also might have been limited by ecological
bias. Obesity has been found to be associated with long-term
cardiovascular risk,23 and long-standing obesity has been
somewhat more strongly associated with cardiovascular
Journal of the American Heart Association

Downloaded from http://jaha.ahajournals.org/ at George Washington University on May 27, 2015

13

ORIGINAL RESEARCH

A White women

Race/Ethnicity, BMI, Metabolism, and CVD Risk

Schmiegelow et al

Strengths and Limitations
This large study is unique in having more black participants
than other studies and thus could evaluate racial and ethnic
differences in the risk of CVD according to obesity and
metabolic health status. Its other strengths include the use of
prospectively collected data with coronary heart disease and
ischemic stroke as adjudicated end points, the long follow-up,
and the available fasting measures of glucose and lipid levels
for 15 000 postmenopausal women without CVD or diabetes.
This study also had several limitations. First, the WHI
enrolled only postmenopausal women, so our results may not
be generalizable either to younger women or to men. Second,
the deﬁnition of metabolically healthy obese varies among
studies,16 although most use either the ATP III8 or the
International Diabetes Federation criteria for the metabolic
syndrome.5,9 Without a uniform deﬁnition of metabolically
DOI: 10.1161/JAHA.114.001695

healthy obese, it is difﬁcult to compare studies.28 We used the
most commonly applied deﬁnition, and our ﬁndings were
unchanged when we applied an alternative, also widely used
deﬁnition of metabolically healthy,9 namely, ≥2 metabolic
abnormalities in addition to obesity (deﬁned as BMI ≥30 or a
waist circumference ≥80 cm). Third, menopausal hormone
therapy increases HDL-C and triglycerides, which should be
taken into account when interpreting the results. Nevertheless, changes induced by hormone therapy were not associated with future risk of coronary heart disease in a WHI
study.29 Fourth, the number of Hispanic women was limited,
so we could not include an interaction term between race, and
the obesity and metabolic abnormality categories in the
model with metabolic health deﬁned by number of metabolic
abnormalities. Instead, we reported the estimates of risk by
race or ethnicity and noted differences that were consistent
with our hypothesis and that should be formally tested in
future studies designed to have adequate statistical power.
The uncertainty surrounding the estimates in the Hispanic
women was greater because of the relatively small number of
Hispanic women in the cohort. Finally, muscle tissue
composes a smaller proportion of overall body mass in
postmenopausal women, thus BMI may be lower in these
women despite higher fat mass.
In conclusion, in postmenopausal women without diabetes
or prior CVD, the presence of even a few metabolic
abnormalities was more strongly associated with increased
cardiovascular risk in black overweight and black obese
women than in white women. Women with ≤1 metabolic
abnormality who were overweight or obese did not appear to
have increased risk of CVD regardless of race or ethnicity.
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risk.24 The Norwegian HUNT study found that being obese but
metabolically healthy was not associated with increased risk
of myocardial infarction but with increased risk of heart
failure,9 whereas a study of younger persons found that the
composite cardiovascular risk (myocardial infarction, stroke,
coronary revascularization) of the metabolically healthy obese
group was comparable to normal weight metabolically healthy
persons only in analyses adjusted for ﬁtness.5 In our study,
adjustment for the level of physical activity did not change the
results, perhaps because the WHI population was older and
female. Furthermore, in a recent Korean cross-sectional
study, being metabolically healthy obese (obese without any
metabolic syndrome components and homeostasis model
assessment for insulin resistance <2.5) was associated with
subclinical coronary atherosclerosis but not after adjustment
for lipids (LDL-C, HDL-C, and triglycerides), systolic blood
pressure, homeostasis model assessment for insulin resistance, and glucose.25 These ﬁndings suggest that obesity is
not a harmless condition because it is closely correlated with
increased risk of insulin resistance and risk of developing
metabolic abnormalities.26 Indeed, a recently published study
found that after 5 years of follow-up, 31.8% of metabolically
healthy obese individuals (deﬁned as BMI ≥30 and ≤1
metabolic syndrome component, 75% men) had become
metabolically unhealthy, rising to 51.5% after 20 years.27 In
the absence of metabolic syndrome, obesity might still be
associated with increased metabolic risk among black women
and thus the need for lifestyle intervention as a “window of
opportunity.” Our ﬁndings underscore the importance of
preventing the development of metabolic disorders, particularly in black overweight and obese women, in whom
metabolic disorders were more strongly associated with
increased cardiovascular risk than in white women.

Race/Ethnicity, BMI, Metabolism, and CVD Risk

Schmiegelow et al

None.

16. Kramer CK, Zinman B, Retnakaran R. Are metabolically healthy overweight and
obesity benign conditions?: A systematic review and meta-analysis. Ann Intern
Med. 2013;159:758–769.
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